Eton Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company has six commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. INCRELEX is a biologic product used to treat pediatric patients 2 years of age and older who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. Carglumic Acid is for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is for the treatment of homocystinuria. Nitisinone is for the treatment of hereditary tyrosinemia type 1 (HT-1). PKU GOLIKE is a medical formula for patients with phenylketonuria (PKU). Galzin, its product, is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 152.67% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 79.95M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 79.95M.
Undervalued
The company’s latest PE is -659.17, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 15.99M shares, decreasing 18.71% quarter-over-quarter.
Held by ETHSX
Star Investor ETHSX holds 15.71K shares of this stock.